| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2022―Dec―15 |
Lenzilumab. Anti-GM-CSF monoclonal antibody, Treatment of chronic myelomonocytic leukemia, Treatment of COVID-19 |
A.M. Kalaiger, M. Assi, Z . Temesgen |
| 2 |
[GO] |
2022―Nov―15 |
An overview of prophylaxis and treatment indications for COVID-19-related thrombotic complications. Review of the recent literature |
A. Moreno-Castaño, G. Escolar, M. Diaz-Ricart |
| 3 |
[GO] |
2021―Dec―13 |
Molnupiravir. RNA-directed RNA polymerase (RdRp) inhibitor, Treatment of mild to moderate COVID-19 |
G. Kaul, A. Dasgupta, S. Chopra |
| 4 |
[GO] |
2021―Oct―22 |
Repurposing approach of fluvoxamine for COVID-19 |
M.W. McCarthy |
| 5 |
[GO] |
2021―Sep―22 |
Investigational antiviral drugs for the treatment of COVID-19 |
C.T.R. Vegivinti, M. Assi, R. Talwani, V. Koblizek, K. Burke, Z. Temesgen |
| 6 |
[GO] |
2021―Sep―22 |
Investigational immunomodulatory therapies for COVID-19 |
M. Assi, K.M. Koshy, W. El Atrouni, K. Burke, M. Berg, A. Opardija, Z. Temesgen |
| 7 |
[GO] |
2020―Jun―08 |
Remdesivir. RNA-dependent RNA polymerase inhibitor, Treatment of Ebola virus infection, Treatment of SARS-CoV-2 infection (COVID-19) |
|
| 8 |
[GO] |
2020―May―05 |
Taking aim at a fast-moving target: targets to watch for SARS-CoV-2 and COVID-19 |
L. Sorbera, A. Graul, C. Dulsat |
